ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology
June 7, 2022
The ADARx Team
San Diego, California, June 7, 2022 – ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.
“I am delighted to welcome Andrew to the ADARx team, as his wealth of experience in the biotech industry will greatly enhance our capabilities,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Andrew has deep expertise across key aspects of development from preclinical studies to NDA submission and his leadership offers great benefit to the company as we continue to expand our pipeline and advance programs to the clinic.”
Dr. Seacat has over 20 years of experience in nonclinical drug development, toxicology, and drug safety evaluation and, in his new role, will lead all GLP and non-GLP toxicology studies for our RNA-targeting therapeutics. Dr. Seacat was most recently Senior Director, Pharmacology and Toxicology at Zogenix (a wholly owned subsidiary of UCB S.A.) where he led authoring of all non-clinical sections of an NDA. Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals and Senior Director, Preclinical Development at La Jolla Pharmaceuticals. He also had increasing roles of responsibility in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Medical Department. Dr. Seacat received a Doctorate in Biochemical Molecular Toxicology and completed a Postdoctoral Fellowship at Johns Hopkins University. Dr Seacat was also Diplomate of the American Board of Toxicology (DABT2001-2015).
ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are at IND-enabling stage.